# OnCo record paper-anbl1221-expansion-dinutuximab-gm-csf-mody-jco-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-anbl1221-expansion-dinutuximab-gm-csf-mody-jco-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-anbl1221-expansion-dinutuximab-gm-csf-mody-jco-2020" ;
  schema:name "ANBL1221 expansion: irinotecan, temozolomide and dinutuximab with GM-CSF in refractory or relapsed neuroblastoma"@en ;
  schema:description "Across 53 children treated with irinotecan, temozolomide and dinutuximab for relapsed neuroblastoma, four in ten had their tumours shrink and 85 percent were alive a year later, confirming the combination as the standard salvage treatment."@en ;
  schema:url <https://onco.cc/key-papers/paper-anbl1221-expansion-dinutuximab-gm-csf-mody-jco-2020/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.20.00203>, <https://pubmed.ncbi.nlm.nih.gov/32343642/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.20.00203> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Mody R, Yu AL, Naranjo A, et al." ;
  onco:cancers <https://onco.cc/cancers/neuroblastoma-high-risk/>, <https://onco.cc/cancers/neuroblastoma/> ;
  onco:drugs <https://onco.cc/drugs/dinutuximab/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/sargramostim/> ;
  onco:trials <https://onco.cc/trials/anbl1221/> ;
  onco:journals <https://onco.cc/journals/jco/> .